• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

neurodegeneration

Lilly
Biotech

Lilly scraps ph. 2 Alzheimer's program after drug falls short

According to a Lilly spokesperson, the mevidalen program in symptomatic Alzheimer's disease “did not meet our high internal bar for success.”
Marissa Russo Oct 29, 2026 2:09pm
Bristol Myers Squibb booth at AACR 2026

BMS walks away from $80M neurodegeneration bet after phase 1

Oct 29, 2026 10:53am
Darts failing to hit bullseye

Novartis ends ALS program after phase 2 flop, adding to R&D woes

Sep 16, 2026 10:28am
brain art

Novartis pens BioArctic neuro pact worth $30M upfront

Aug 26, 2025 8:30am
Photo of a final puzzle piece about to fit into a puzzle

Lilly pays QurAlis $45M for preclinical ALS, dementia prospect

Jun 3, 2024 5:00am
Mergers  Acquisitions

AbbVie continues Parkinson's pursuit with $110M Mitokinin buy

Oct 5, 2023 10:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings